117 results about "PLG - Plasminogen" patented technology

Disclosed are methods and compositions for producing heterologous disulfide bond containing polypeptides in bacterial cells. In preferred embodiments the methods involve co-expression of a prokaryotic disulfide isomerase, such as DsbC or DsbG and a gene encoding a recombinant eukaryotic polypeptide. Exemplary polypeptides disclosed include tissue plasminogen activator.

This invention encompasses novel leader sequences for production of proteins. More specifically, the invention relates to DNA constructs encoding leader sequences comprising an immunoglobulin signal peptide fused to a tissue-type plasminogen activator propeptide, and to DNA constructs encoding leader sequences comprising a truncated human tissue-type plasminogen activator propeptide. The invention further relates to the use of these DNA constructs for producing proteins in mammalian cells.

The invention discloses a mutant human plasminogen kringle5 gene mK5 and an amplification primer of the mK5 gene, the mutant human plasminogen kringle5 gene modified by adding glutathione-S-transferase before the gene mK5, and a method for preparing protein mK5 recombinant protein of two gene codes, glutathioneS transferase (GST)-mK5 fusion protein and two proteins, wherein the mK5 gene and the GST-mK 5 gene can be applied to preparing medicaments for treating angiogenesis diseases. By the invention, the number of exogenous amino acid in the recombinant K5 protein molecules obtained by a gene engineering method is remarkably reduced, the K5 bioactivity of the obtained mK5 is improved, while the mK5 activity of the GST-mK5 fusion protein is maintained, the stability and water solubility of the protein are improved, the purification steps of an expressed product are simplified, and the purity of the product is improved.

Novel compounds having activity inhibitors of urokinase and in reducing or inhibiting blood vessel formation are provided. These compounds have an arginine or arginine mimic aldehyde or an arginine ketoamide group at P1. These compounds are useful in vitro for monitoring plasminogen activator levels and in vivo in treatment of conditions which are ameliorated by inhibition of or decreased activity of urokinase and in treating pathologic conditions wherein blood vessel formation is related to a pathologic condition.

A functional mutant of human plasminogen disclosed in the invention, respectively, is hPLG-delta K: human plasminogen protein Pro<544>-Asn<791> polypeptide; Pro<559> in RGD-hPLG-delta K: hPLG-delta K is mutated to Asp<559>; and Gly<560> in RHP-hPLG-delta K: hPLG-delta K polypeptide is mutated to His<560>. The invention also discloses a preparation method for the functional mutant. The product is obtained by using a plasmid containing a full-length cDNA sequence of human plasminogen as a template to carry out a PCR to construct a plasmid and using Pichia Pastoris expression. The functional mutant has a dual-function of fibrinolysis and inhibiting platelet aggregation or inhibiting fibrin monomer polymerization.

The invention provides a fusion protein formed by the combination of urokinase-type plasminogen activator a chain and melittin, the preparation method thereof, and the application of the fusion protein in tumor treatment.

The present invention relates generally to a method of reducing the level of plasminogen and/or tissue plasminogen activator and/or other protease(s) in a solution comprising fibrinogen and/or Factor VIII and/or von Willebrand factor (VWF), the method comprising: (i) passing a feedstock comprising fibrinogen and/or Factor VIII and/or VWF through a hydrophobic charge-induction chromatographic resin under conditions selected such that the plasminogen and/or tissue plasminogen activator and/or other protease(s) is bound to the resin; and (ii) recovering the solution comprising fibrinogen and/or Factor VIII and/or VWF which passes through the resin; wherein the concentration of the plasminogen and/or tissue plasminogen activator and/or protease(s) in the recovered solution is reduced by at least 50% compared to the feedstock. Also provided are solutions and pharmaceutical formulations comprising the fibrinogen and/or Factor VIII and/or VWF recovered by such methods, and uses thereof.

Identification of urokinase-type plasminogen, matrix metalloproteinase 9, and β-2-microglobulin as novel biomarkers associated with liver fibrosis and uses thereof in diagnosing liver fibrosis.

The present invention provides compositions and methods for inhibiting abnormal cell growth. In particular, the invention provides nucleic acids encoding Diphtheria toxin fusion proteins comprising residues 1-388 of Diphtheria toxin, wherein the native furin cleavage site has been substituted for a matrix metalloproteinase or plasminogen activator cleavage site, and a heterologous polypeptide and the polypeptides encoded by such nucleic acids. In addition, the invention provides methods of treating cancer by administering such polypeptides.

The present invention relates to the extraction of fibrinolysin as new type of thromboliytic medicine from rhizopchin. The fibrinolysin has molecular weight 30.5 KD, isoelectric point 8.5, and double effects of directly dissolving thrombus and activating human plasminogen. The production process includes three stages, of culture of rhizopchin including slant culture, seed culture and fermentation culture; and separating and purifying fermented liquid to obtain fibrinolysin. The product is safe, non-toxic and cheap and the production process uses cheap agricultural side product as main material and is a liquid fermentation process. The purification process includes microfiltering to eliminate thallus, decolorizing with ion exchange resin, salting out, ultrafiltering to eliminate salt and hybrid protein and ion exchanging to purify. The present invention has short technological process, low cost and high production efficiency.

The invention relates to plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or disorder associated with elevated PAI-1. The invention includes, but is not limited to, the use of such compounds to prevent or reduce thrombosis and fibrosis, to promote thrombolysis, and to modulate lipid metabolism and treat diseases or disorders associated with elevated PAI-1, cholesterol, or lipid levels.

Antibodies or other ligands specific for the binary uPA-uPAR complexes, for ternary complexes comprising uPA-uPAR and for complexes of uPAR and proteins other than uPA such as integrins inhibit the interaction of uPA and uPAR with additional molecules with which the complexed interact. Such antibodies or other ligands are used in diagnostic and therapeutic methods, particularly against cancer.

The invention discloses a PAlb-uPA slow virus vector, which contains an albumin promoter PAlb, a urokinase plasminogen activator gene uPA, a tetracycline trans-acting factor rtTA/rtTA2S-M2 of the albumin promoter PAlb and a PTight promoter for regulating and controlling the urokinase plasminogen activator gene uPA. The invention further discloses a preparation method and an application of the PAlb-uPA slow virus vector. The preparation method is simple; the obtained slow virus vector can be used for preparing a urokinase fibrinolysis protease mouse liver injury model; and an effective research platform is provided for the clinical research of a human hepatitis virus infection mechanism and an anti-virus medicament.

The present invention provides therapeutic products with decreased fibrinolytic activity of t-PA-deficient and/or plasminogen-deficient blood products, as well as compositions, kits and methods using the same in treating bleeding associated with hereditary or acquired bleeding disorders. The invention further provides extracorporeal apparatus for blood or blood products Plasmapheresis aimed to prevent or treat bleeding disorders.

Human plasminogen activator analog peptide and its production are disclosed. It is based on protein molecule interaction critical theory and uses solvent of streptokinase and glycosylzyme as mechanism. It is carried out by taking human plasminogen as target protein by surface displaying technology of phagicin random polypeptide base, biological elutriating, screening, obtaining polypeptide sequence with mu Pg high affinity, and solid-phase synthesizing the analog peptide. Its advantages include small molecular weight, low immunity, simple process and easy control of product output, purity and activity. It can be used to prepare oral preparation and prevent thrombogenesis.

The invention relates to inhibitors of the urokinase-type plasminogen activator receptor (uPAR). The generated inhibitors are bivalent uPAR-ligands containing the receptor binding domains of the extracellular protease urokinase-type plasminogen activator (uPA) and of the extracellular matrix protein vitronectin (VN), in different configurations, linked by a scaffold. The present invention also refers to the above molecules for use as a medicament, in particular for treatment of cancer, and for diagnostic purposes.

The present invention discloses the use of plasminogen to regulate GLP-1/GLP-1R and treat a GLP-1/GLP-1R-related condition.

The present invention relates to a fibrin sealant kit comprising purified fibrinogen and thrombin. The invention particularly relates to an improved chromatographic process for the purification of thrombin and fibrinogen components devoid of any significant plasminogen and other impurities. The absence of plasminogen facilitates the exclusion of a proteolytic inhibitor (aprotinin) from among the kit components.

The invention discloses a protein chip for combined detection of multiple thrombus markers. A preparation method of the protein chip comprises the following steps: (1) black slide pretreatment; (2) antibody solution sample application; (3) a sealing process; and preparation of the protein chip. The protein chip is used for detecting concentrations of various thrombus markers, preventing and reducing thrombus risks and guiding thrombus treatment. The product disclosed by the invention is a protein chip diagnostic kit comprising six indexes of TAT (thrombin-antithrombin complex), PIC (plasmin-alpha2 anti-plasminogen complex), tPAIC (tissue-type plasminogen activator-plasminogen activation inhibition complex), TM (thrombomodulin), FDP (fibrinogen degradation product) and DD (D-dimer). The indexes are detected by using a protein chip technology for the first time, and the method has the advantages of quickness, high efficiency, simplicity, convenience, low cost and the like.

The invnetion relates to the field of a plant extract, and particularly to use of a young watermelon fruit and a young chiapao melon fruit in preparing a medical composition for gene controlling. Thecomposition which comprises a young watermelon fruit extract, a young chiapao melon fruit extract or combination thereof can promote keratinocyte metabolism and suppression interleukin-8 secretion through up-regulating expression amounts of nitricoxide synthase3 (NOS3) and von Willebrand factor (vWF) gene and down-regulating the expression amounts of interleukin-8 (IL-8), endothelin1 (EDN1), tissue-type plasminogenactivator (PALT), human coagulation factor (F3), serine protease inhibitor1 (SERPINE1) and intercellular adhesion molecule1 (ICAM1) gene, thereby finally realizing effects of anti-inflammation, anti-acne and reducing blood pressure and blood fat.

The present invention provides fusion proteins for targeted delivery of plasminogen activators to platelet-VWF complexes, or alternatively to the site where these are located, in a fibrin-independent manner. The fusion protein of the invention are for use in methods for the prevention or treatment of diseases or conditions associated with such platelet-VWF complexes, which may cause microvascular thrombosis in diseases such as e.g. thrombotic thrombocytopenic purpura. Preferred targeting agents for incorporation into the fusion proteins are e.g. nanobodies against VWF or platelets. Preferred plasminogen activators for use in the fusion proteins comprise the protease domains of uPA or tPA. The invention further pertains to nucleic acid molecule encoding the fusion proteins of the invention, e.g. a gene therapy vector, and to pharmaceutical compositions comprising the fusion proteins of the invention or such gene therapy vectors.